February 9, 2016 — Boston Scientific Corp. announced the Centers for Medicare and Medicaid Services (CMS) will cover ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
February 09, 2016
Feature | Pharmaceuticals | Rosanne M. Crooke, Ph.D.
Familial chylomicronemia syndrome (FCS) is a rare, genetic disease characterized by mutations in genes affecting the ...
January 22, 2016January 4, 2016 — Living with pulmonary arterial hypertension (PH) is challenging, but the chore of treating the rare ...
January 04, 2016
Feature | Genetic Testing | Kevin P. Greene, M.D.
Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by ...
December 22, 2015
December 17, 2015 — The ROCKET AF Clinical Trial Executive Committee announced its secondary analysis of the phase III ...
December 17, 2015November 24, 2015 —The U.S. Court of Appeals has overturned a federal circuit court’s decision in The Medicines Company ...
November 24, 2015FDA Approves Dabigatran for Prophylaxis of DVT, Pulmonary Embolism and After Hip Replacement Surgery
November 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals’ ...
November 24, 2015November 20, 2015 — Boston Heart Diagnostics announced the launch of StatinSmart, an at-home saliva laboratory developed ...
November 20, 2015November 12, 2015 — Preventing blood clots with drugs such as heparin has become a common practice for fighting some ...
November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of ...
November 12, 2015
November 11, 2015 — Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new ...
November 11, 2015
October 23, 2015 — A randomized trial found that ranolazine did not reduce the composite rate of ischemia-driven ...
October 23, 2015
October 20, 2015 — Results from the BRAVO 3 trial found that bivalirudin did not significantly reduce major bleeding ...
October 20, 2015
October 19, 2015 — The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (idarucizumab) ...
October 19, 2015
October 2, 2015 — AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies ...
October 02, 2015